MannKind corporation (NASDAQ:MNKD) facing an independent panel of experts and the U.S. Food and Drug Administration (FDA) on Tuesday, April 1, regarding the safety issue and efficacy of its product Afrezza. MannKind Corporation (NASDAQ:MNKD) shares after opening at $4.44 moved to $4.60 on last trade day and at the end of the day closed at $4.02. Company price to cash ratio as 21.42. MannKind Corporation (NASDAQ:MNKD) showed a negative weekly performance of -31.98%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) reported in the previous week, that it had initiated phase 1 testing of its drug candidate RX3117 which has been designed to treat cancer. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares fell -5.26% in last trading session and ended the day on $1.08. RNN return on equity ratio is recorded as -81.70% and its return on assets is -49.00%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) yearly performance is 227.27%.
Marina Biotech, Inc. (OTCMKTS:MRNA) has been trading downwards in the past three trading session on volumes. The company earlier announced a receipt of new patent in Japan for its SMARTICLES(R) delivery technology. The company currently plans to develop drugs to cure rare diseases. Marina Biotech, Inc. (OTCMKTS:MRNA) shares moved down -17.59% in last trading session and was closed at $0.890, while trading in range of $0.86 – $1.09. Marina Biotech, Inc. (OTCMKTS:MRNA) year to date (YTD) performance is 122.50%.
Fate Therapeutics Inc. (NASDAQ:FATE) recently announced fourth quarter loss of 29 cents per share and no revenue, meeting Zacks consensus on earnings, exceeding the $3.51 loss per share noted in the comparable quarter a year ago. Shares of Fate Therapeutics Inc. (NASDAQ:FATE) were up 11.64 percent to $12.28 during Wednesday session. Fate Therapeutics Inc. (NASDAQ:FATE) weekly performance is -14.19%. On last trading day company shares ended up $9.74. Fate Therapeutics Inc. (NASDAQ:FATE) distance from 50-day simple moving average (SMA50) is 23.09%. Analysts mean target price for the company is $14.50.